Publications by authors named "N Tappenbeck"
Ex vivo-expanded highly pure ABCB5 mesenchymal stromal cells as Good Manufacturing Practice-compliant autologous advanced therapy medicinal product for clinical use: process validation and first in-human data.
Andreas Kerstan Elke Niebergall-Roth Jasmina Esterlechner Hannes M Schröder Martin Gasser Nils Tappenbeck
Cytotherapy
February 2021
Article Synopsis
- Mesenchymal stromal cells (MSCs) are being explored for treating tissue damage, but their varying properties may explain inconsistent results in therapy; a specific MSC subset identified by the ABCB5 transporter has shown potential for improved outcomes.
- The researchers developed a compliant process to isolate and produce ABCB5 MSCs from skin, leading to a product approved for clinical trials aimed at treating chronic venous ulcers.
- Early results from treating nine patients show a significant median reduction in wound size (63%) after 12 weeks, suggesting that ABCB5 MSCs might provide an effective solution for challenging chronic wounds.
Article Synopsis
- The authors are submitting a corrigendum, which means they want to correct or clarify something in a previously published article.
- They express gratitude for the consideration of their request.
- They are hopeful for the publication of the correct information.
Article Synopsis
- Liver transplantation is a viable treatment for end-stage liver diseases but faces challenges like high costs, long waitlists, and limited organ availability, prompting interest in stem cell therapies as a potential alternative.
- ABCB5 cells, which are easily obtained from skin and have shown potential in treating skin injuries, were tested for their effects on liver injury in Mdr2KO mice through intravenous injections, focusing on inflammation, fibrosis, and cellular behaviors.
- The study found that ABCB5 cells did not cause toxicity and positively influenced liver health by reducing collagen deposition and apoptosis, while also promoting cell proliferation and activating beneficial signaling pathways in liver cells.
Article Synopsis
- - The study focuses on ABCB5-expressing mesenchymal stromal cells (MSCs) from human skin as a potential therapy for currently untreatable diseases, having developed a method to isolate and process these cells in line with international safety standards.
- - Extensive safety testing was conducted on ABCB5 MSCs, revealing no harmful effects such as abnormal cell growth, tumor formation, or adverse tissue reactions in animal models.
- - Results indicate that ABCB5 MSCs are safe and tolerable for local and systemic use, supporting their development as a new advanced-therapy medicinal product.
The continuously decreasing willingness for liver donation aggravates treatment of end-stage liver diseases requiring organ transplantation as the only curative strategy. Cell therapy approaches using human hepatocytes or stem cell-derived hepatocyte-like cells may be a therapeutic option out of this dilemma. ABCB5-positive mesenchymal stromal cells from human skin featured promising potential to treat immune-mediated diseases.
View Article and Find Full Text PDF